Existing targeted therapies have secured optimization of selective efficacy, but in most cases, when used alone, the therapeutic effect is lowered due to drug resistance. This is because it promotes resistance in cells or individuals receiving targeted drug therapy, resulting in drug resistance and relapse. In recent years, combination drug prescription and treatment have been used as effective treatments for tumors and infectious diseases.

Therefore, Neocannbio intends to develop a safe synergistic combination drug that can reduce tolerance problems and lower the side effects of drugs through research on the development of combined effects with cannabinoids using anticancer drugs and metabolic disease treatments.